search
ImmunityBio
Trends
- 1Retail Traders Eye SLS, IBRX After Moderna's Nasdaq-100 Entry▼SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Retail investors are speculating about small-cap biotech stocks Sellas Life Sciences (SLS) and ImmunityBio (IBRX) after Moderna (MRNA) was added to the Nasdaq-100 index. Some traders are betting one of the two could be next to earn a spot in the benchmark index, fueling buzz around the names on social trading platforms. Index inclusion typically drives demand from funds tracking the Nasdaq-100, which is why traders watch additions closely for potential stock moves.
- 2ImmunityBio Shares Post Best Week In Months On Trump Cancer Panel Pick▼IBRX Stock Logs Best Week In Over 7 Months: Retail Eyes Anktiva Boost From Trump’s Cancer Panel Pick
ImmunityBio stock (IBRX) wrapped up its strongest week in more than seven months as retail investors bet its bladder cancer drug Anktiva could benefit from the Trump administration's choice to lead a cancer-focused advisory panel. Traders are speculating the pick could speed adoption or funding for Anktiva, driving renewed buying interest in the biotech.
- 3Retail biotech favorites SLS, IBRX, VNDA, IOVA vs September slump▼Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
Biotech stocks lagged the broader market in September, with the SPDR S&P Biotech ETF (XBI) falling while the wider market held up better. Attention is now on whether retail-favored names SELLAS Life Sciences (SLS), ImmunityBio (IBRX), Vanda Pharmaceuticals (VNDA) and Iovance Biotherapeutics (IOVA) managed to escape the sector's slump. Investors are weighing whether these popular small-cap biotechs diverged from the wider sector weakness.